Photo of Marlise R. Luskin, MD, MSCE

Marlise R. Luskin, MD, MSCE

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute


Marlise_Luskin@dfci.harvard.edu

Photo of Marlise R. Luskin, MD, MSCE

Dana-Farber Cancer Institute


Marlise_Luskin@dfci.harvard.edu

Member Summary Video
Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Marlise R. Luskin, MD, MSCE but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members

Marlise R. Luskin, MD, MSCE

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am a member of the Adult Leukemia Program at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital. My primary research interest is conducting clinical trials of novel agents for acute leukemias and related blood cancers (myelodysplastic syndromes and myeloproliferative neoplasms). I also have an interest in conducting clinical epidemiology and outcomes research for patients with these diseases. I earned a Master’s of Science in Clinical Epidemiology (MSCE) during my fellowship (2012-2015) at the University of Pennsylvania which provided important foundation in clinical trials and clinical epidemiology research. This program included coursework in biostatistics, epidemiology, research methodology, clinical trial design, and database management, as well as an independent thesis project. My thesis investigated the prognostic ability of a novel methylation-based biomarker (M-score) in de novo AML. This research showed that a classifier based on the M-score is excellent at identifying AML subgroups with differing clinical outcome. I confirmed the performance of the M-score classifier in key AML subgroups and in an independent cohort of patients enrolled in a ECOG study (JCI Insight 2016). In addition to my thesis, I have completed several other epidemiologic studies including one study that identified an association of mutated NPM1 with the development of leukemia cutis (Haematologica 2015) and another showing that high-risk AML subgroups (including patients with FLT3-ITD) benefit from high-dose daunorubicin induction (Blood 2016). More recently, I completed a project showing that poor sleep is associated with inferior outcomes in MDS (British Journal of Hematology 2016). I have also been involved in the design and completion of several therapeutic trial. While a fellow at the University of Pennsylvania, I wrote a pilot/phase I trial to evaluate the feasibility, safety, and efficacy of adding interferon-α to donor lymphocyte infusion for treatment of patients with relapsed acute leukemia after allogeneic stem cell transplantation. After joining the faculty at DFCI, I completed the Methods in Clinical Research Course designed to provide intensive training to PIs conducting trials at DFCI. Since completing that course, I have assumed the role as site PI for multiple for acute leukemia at DFCI. I am the PI for a CTEP-sponsored study of blinatumomab in combination with checkpoint blockade for patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) as well as an industry-sponsored study of a HSP90 inhibitor for relapse/refractory FLT3-ITD mutant AML. I have also personally written and obtained FDA, industry, and IRB approval for an IST which will soon open investigating a novel TKI in the initial treatment of BCR-ABL+ B-cell ALL: Phase 1 study of ABL001 in combination with dasatinib and prednisone in patients with BCR-ABL positive B-cell acute lymphoblastic leukemia (BCR-ABL+ B-ALL) and chronic myeloid leukemia (CML).

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Valtis YK, Flamand Y, Shimony S, Place AE, Silverman LB, Vrooman LM, Brunner AM, Sallan SE, Wadleigh M, Stone RM, DeAngelo DJ, Luskin MR. Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia 2024. PubMed
  • Stevens MM, Kimmerling RJ, Olcum S, Vacha M, LaBella R, Minnah A, Katsis K, Fujii J, Shaheen Z, Sundaresan S, Criscitiello J, Niesvizky R, Raje N, Branagan A, Krishnan A, Jagannath S, Parekh S, Sperling AS, Rosenbaum CA, Munshi N, Luskin MR, Tamrazi A, Reid CA. Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies. JCO Precis Oncol 2024; 8:e2300349. PubMed
  • Saygin C, Zhang P, Stauber J, Aldoss I, Sperling AS, Weeks LD, Luskin MR, Knepper TC, Wanjari P, Wang P, Lager AM, Fitzpatrick C, Segal JP, Gharghabi M, Gurbuxani S, Venkataraman G, Cheng JX, Eisfelder BJ, Bohorquez O, Patel AA, Umesh Nagalakshmi S, Jayaram S, Odenike OM, Larson RA, Godley LA, Arber DA, Gibson CJ, Munshi NC, Marcucci G, Ebert BL, Greally JM, Steidl U, Lapalombella R, Shah BD, Stock W. Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis. 2023. PubMed
  • Lane AA, Garcia JS, Raulston EG, Garzon JLN, Galinsky I, Baxter EW, Leonard R, DeAngelo DJ, Luskin MR, Reilly CR, Stahl M, Stone RM, Vedula RS, Wadleigh M, Winer ES, Mughal TI, Brooks C, Gupta IV, Stevenson KE, Neuberg DS, Ren S, Keating JH, Konopleva MY, Stein AS, Pemmaraju N. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv 2023. PubMed
  • Shimony S, Luskin MR. Approach to Older Adults With Philadelphia-Chromosome Negative Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 2023. PubMed
  • Sadigh S, DeAngelo DJ, Garcia JS, Hasserjian RP, Hergott CB, Lane AA, Lovitch SB, Lucas F, Luskin MR, Morgan EA, Pinkus GS, Pozdnyakova O, Rodig SJ, Shanmugam V, Tsai HK, Winer ES, Zemmour D, Kim AS. Cutaneous Manifestations of Myeloid Neoplasms Exhibit Broad and Divergent Morphologic and Immunophenotypic Features but Share Ancestral Clonal Mutations With Bone Marrow. Mod Pathol 2023; 37:100352. PubMed
  • Paolino J, Dimitrov B, Apsel Winger B, Sandoval-Perez A, Rangarajan AV, Ocasio-Martinez N, Tsai HK, Li Y, Robichaud AL, Khalid D, Hatton C, Gillani R, Polonen P, Dilig A, Gotti G, Kavanagh J, Adhav AA, Gow S, Tsai J, Li Y, Ebert BL, Van Allen EM, Bledsoe J, Kim AS, Tasian SK, Cooper SL, Cooper TM, Hijiya N, Sulis ML, Shukla NN, Magee JA, Mullighan CG, Burke MJ, Luskin MR, Mar BG, Jacobson MP, Harris MH, Stegmaier K, Place AE, Pikman Y. Integration of genomic sequencing drives therapeutic targeting of PDGFRA in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. Clin Cancer Res 2023. PubMed
  • AlJabban A, Paik H, Aster JC, Berliner N, Brouillard J, Brown JR, Burns KH, Castillo JJ, Card J, Dal Cin P, DeAngelo DJ, Dorfman DM, Ebert BL, Garcia JS, Jacobson CA, Lakhani H, Laubach JP, Ligon AH, Lindeman NI, Lindsley RC, Lovitch SB, Luskin MR, Morgan EA, Nowak A, Petrides A, Pinkus GS, Pozdnyakova O, Steensma DP, Stone RM, Weinberg OK, Winer ES, Kim AS. Optimization of Advanced Molecular Genetic Testing Utilization in Hematopathology: A Goldilocks Approach to Bone Marrow Testing. JCO Oncol Pract 2023. PubMed
  • Stahl M, Giblin G, Liu Y, Winer ES, Garcia JS, Chen E, Wadleigh M, Ling K, Lindsley RC, Shimony S, Copson K, Charles A, DeAngelo DJ, Stone RM, Nohria A, Luskin MR. Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia. Leuk Res 2023; 132:107351. PubMed
  • Hantel A, Luskin MR, Khan I, Warner E, Patel AA, Walsh TP, DeAngelo DJ, Lathan CS, Abel GA. Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia. Haematologica 2023. PubMed
  • Shimony S, Flamand Y, Valtis YK, Place AE, Silverman LB, Vrooman LM, Brunner AM, Sallan SE, Stone RM, Wadleigh M, Neuberg DS, DeAngelo DJ, Luskin MR. Effect of BMI on Toxicities and Survival Among Adolescents and Young Adults Treated on DFCI Consortium ALL Trials. Blood Adv 2023. PubMed
  • Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, Turkalj S, Jakobsen NA, Luskin MR, Duose DY, Tidwell RSS, Short NJ, Borthakur G, Kadia TM, Masarova L, Tippett GD, Bose P, Jabbour EJ, Ravandi F, Daver NG, Garcia-Manero G, Kantarjian H, Garcia JS, Vyas P, Takahashi K, Konopleva M, DiNardo CD. A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies. 2023; 4:276-293. PubMed
  • Shimony S, DeAngelo DJ, Luskin MR. Nelarabine: When, Where and How to Use it When Treating T-cell Acute Lymphoblastic Leukemia. Blood Adv 2023. PubMed
  • Shimony S, Fell GG, Chen EC, Tsai HK, Wadleigh M, Winer ES, Garcia JS, Luskin MR, Stahl M, Neuberg DS, DeAngelo DJ, Lindsley RC, Stone RM. FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients age ≥60 years. Blood Adv 2023. PubMed
  • Weeks LD, Niroula A, Neuberg D, Wong W, Lindsley RC, Luskin M, Berliner N, Stone RM, DeAngelo DJ, Soiffer R, Uddin MM, Griffin G, Vlasschaert C, Gibson CJ, Jaiswal S, Bick AG, Malcovati L, Natarajan P, Ebert BL. Prediction of risk for myeloid malignancy in clonal hematopoiesis. NEJM Evid 2023. PubMed
  • Luskin MR, Lane AA. Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm. Haematologica 2023. PubMed
  • Knoerl R, Mazzola E, Woods H, Buchbinder E, Frazier L, LaCasce A, Luskin MR, Phillips CS, Thornton K, Berry DL, Ligibel J. Exploring Influencing Factors of Anxiety Improvement Following Mindfulness-Based Music Therapy in Young Adults with Cancer. J Music Ther 2023. PubMed
  • Phillips CS, Bockhoff J, Berry DL, Buchbinder E, Frazier AL, LaCasce A, Ligibel J, Luskin MR, Woods H, Knoerl R. Exploring Young Adults' Perspectives of Participation in a Mindfulness-Based Music Therapy Intervention Before and During the COVID-19 Pandemic. J Adolesc Young Adult Oncol 2023. PubMed
  • Raman HS, Kim SE, DeAngelo DJ, Stevenson KE, Neuberg D, Winer ES, Wadleigh M, Garcia JS, Kim AS, Stone RM, Ho VT, Luskin MR. Intensity of induction regimen and outcomes among adults with Ph+ALL undergoing allogeneic hematopoietic stem cell transplantation. Leuk Res 2023; 125:107004. PubMed
  • El-Jawahri A, Luskin MR, Greer JA, Traeger L, Lavoie M, Vaughn DM, Andrews S, Yang D, Boateng KY, Newcomb RA, Ufere NN, Fathi AT, Hobbs G, Brunner A, Abel GA, Stone RM, DeAngelo DJ, Wadleigh M, Temel JS. Psychological mobile app for patients with acute myeloid leukemia (AML): A pilot randomized clinical trial. Cancer 2023. PubMed
  • Chen EC, Gandler H, Tošić I, Fell GG, Fiore A, Pozdnyakova O, DeAngelo DJ, Galinsky I, Luskin MR, Wadleigh MS, Winer ES, Leonard R, O'Day K, de Jonge A, Neuberg D, Look AT, Stone RM, Frank DA, Garcia JS. Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates. Clin Cancer Res 2022. PubMed
  • Shimony S, Liu Y, Valtis YK, Paolino JD, Place AE, Brunner AM, Weeks LD, Silverman LB, Vrooman LM, Neuberg D, Stone RM, DeAngelo DJ, Luskin MR. Nelarabine Combination Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Lymphoma/Leukemia. Blood Adv 2022. PubMed
  • Kimmerling RJ, Stevens MM, Olcum S, Minnah A, Vacha M, LaBella R, Ferri M, Wasserman SC, Fujii J, Shaheen Z, Sundaresan S, Ribadeneyra D, Jayabalan DS, Agte S, Aleman A, Criscitiello JA, Niesvizky R, Luskin MR, Parekh S, Rosenbaum CA, Tamrazi A, Reid CA. A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements. Commun Biol 2022; 5:1295. PubMed
  • Garcia JS, Flamand Y, Penter L, Keng M, Tomlinson B, Mendez LM, Koller PB, Cullen N, Arihara Y, Pfaff KL, Wolff JO, Brunner AM, Galinsky I, Bashey A, Antin JH, Cutler CS, Ho VT, Jonas BA, Luskin MR, Wadleigh M, Winer ES, Savell A, Leonard R, Robertson T, Davids MS, Streicher H, Rodig SJ, Ritz J, Wu CJ, DeAngelo DJ, Neuberg D, Stone RM, Soiffer RJ. Ipilimumab plus decitabine for patients with MDS or AML in post-transplant or transplant naïve settings. Blood 2022. PubMed
  • Luskin MR. EXABS-132-ALL Approach to Acute Lymphoblastic Leukemia in The Elderly. Clin Lymphoma Myeloma Leuk 2022; 22 Suppl 2:S34-S38. PubMed
  • Curran E, Muffly L, Luskin MR. Innovative Approaches to the Management of Acute Lymphoblastic Leukemia Across the Age Spectrum. Am Soc Clin Oncol Educ Book 2022; 42:1-11. PubMed
  • Knoerl R, Mazzola E, Woods H, Buchbinder E, Frazier L, LaCasce A, Li BT, Luskin MR, Phillips CS, Thornton K, Berry DL, Ligibel JA. Exploring the Feasibility of a Mindfulness-Music Therapy Intervention to Improve Anxiety and Stress in Adolescents and Young Adults with Cancer. J Pain Symptom Manage 2022; 63:e357-e363. PubMed
  • Valtis YK, Place AE, Silverman LB, Vrooman LM, DeAngelo DJ, Luskin MR. Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia. British Journal of Haematology 2022. PubMed
  • Chen EC, Liu Y, Harris CE, Winer ES, Wadleigh M, Lane AA, Vedula RS, Lindsley RC, Copson KM, Charles A, Marty F, Neuberg D, DeAngelo DJ, Stone RM, Luskin MR, Issa NC, Garcia JS. Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leuk Lymphoma 2022. PubMed
  • Schaefer EJ, Wang HC, Karp HQ, Meyer CA, Cejas P, Gearhart MD, Adelman ER, Fares I, Apffel A, Lim K, Xie Y, Gibson CJ, Schenone M, Murdock HM, Wang ES, Gondek LP, Carroll MP, Vedula RS, Winer ES, Garcia JS, Stone RM, Luskin MR, Carr SA, Long HW, Bardwell VJ, Figueroa ME, Lindsley RC. BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target Genes. 2022; 3:116-135. PubMed
  • Van Egeren D, Kamaz B, Liu S, Nguyen M, Reilly CR, Kalyva M, DeAngelo DJ, Galinsky I, Wadleigh M, Winer ES, Luskin MR, Stone RM, Garcia JS, Hobbs GS, Michor F, Cortes-Ciriano I, Mullally A, Hormoz S. Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms. Exp Hematol 2022; 107:14-19. PubMed
  • Kayser S, Sartor C, Luskin MR, Webster J, Giglio F, Panitz N, Brunner AM, Fante M, Lutz C, Wolff D, Ho AD, Levis MJ, Schlenk RF, Papayannidis C. Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin. Haematologica 2022. PubMed
  • Chen SX, Lopez CG, Kassamali B, Luskin MR, Charrow A. Hidradenitis suppurativa in acute myeloid leukemia: Review of disease course and management. JAAD Case Rep 2022; 19:44-47. PubMed
  • Luskin MR. Mini-Hyper-CVD Combinations for Older Adults: Results of Recent Trials and a Glimpse into the Future. Clin Lymphoma Myeloma Leuk 2021. PubMed
  • Hantel A, Luskin MR, Garcia JS, Stock W, DeAngelo DJ, Abel GA. Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials. Blood Adv 2021; 5:4352-4360. PubMed
  • Valtis YK, Stevenson KE, Place AE, Silverman LB, Vrooman LM, Gotti G, Brunner AM, Nauffal M, DeAngelo DJ, Luskin MR. Orthopedic Toxicities Among Adolescents and Young Adults Treated on DFCI ALL Consortium Trials. Blood Adv 2021. PubMed
  • Mueller SB, Dal Cin P, Le LP, Dias-Santagata D, Lennerz JK, Iafrate AJ, Marble H, Brunner AM, Weinstock M, Luskin MR, DeAngelo DJ, Stone RM, Nardi V. t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. Blood Adv 2021. PubMed
  • Tsai FD, Guercio B, Stuver S, Stern R, Peluso MJ, Winkler M, Piawah S, Vallurupalli M, Luskin MR, Braun D, Parent A, Glotzbecker B, Kilbridge KL. Resident-Reported Impact of a Novel Oncology Curriculum for Internal Medicine Residents. J Cancer Educ 2021. PubMed
  • Kayser S, Kramer M, Martínez-Cuadrón D, Grenet J, Metzeler KH, Sustkova Z, Luskin MR, Brunner AM, Elliott MA, Gil C, Marini SC, Ráčil Z, Cetkovsky P, Novak J, Perl AE, Platzbecker U, Stölzel F, Ho AD, Thiede C, Stone RM, Röllig C, Montesinos P, Schlenk RF, Levis MJ. Characteristics and outcome of patients with core binding factor acute myeloid leukemia and -ITD: results from an international collaborative study. Haematologica 2021. PubMed
  • Aleissa MM, Alshehri BS, Gonzalez-Bocco IH, McDonnell AM, Leblebjian H, Marty FM, Luskin MR. Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib. Leuk Res 2021; 108:106610. PubMed
  • Wang D, He K, Sroussi H, Treister N, Luskin M, Villa A, Woo SB, Shazib MA. Oral myeloid sarcoma as an uncommon manifestation of acute myeloid leukemia: A case series and review of the literature. J Am Dent Assoc 2021; 152:393-400.e8. PubMed
  • Haydu JE, Flamand Y, Vedula RS, Versluis J, Charles A, Copson KM, Stone RM, DeAngelo DJ, Neuberg D, Lindsley RC, Luskin MR. Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction. Am J Hematol 2021. PubMed
  • Chen EC, Li S, Eisfeld AK, Luskin MR, Mims A, Jones D, Antin JH, Cutler CS, Koreth J, Ho VT, Gooptu M, Romee R, El-Jawahri A, McAfee SL, DeFilipp Z, Soiffer RJ, Chen YB, Fathi AT. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther 2021. PubMed
  • Van Egeren D, Escabi J, Nguyen M, Liu S, Reilly CR, Patel S, Kamaz B, Kalyva M, DeAngelo DJ, Galinsky I, Wadleigh M, Winer ES, Luskin MR, Stone RM, Garcia JS, Hobbs GS, Camargo FD, Michor F, Mullally A, Cortes-Ciriano I, Hormoz S. Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. Cell Stem Cell 2021. PubMed
  • Raman HS, Shanmugam V, Li J, Steensma DP, Kim AS, Luskin MR. NPM1-mutant acute myeloid leukemia relapsing as acute lymphoblastic leukemia with clonal persistence of IDH1 mutation. Leuk Lymphoma 2021. PubMed
  • Luskin MR. Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy? Hematology Am Soc Hematol Educ Program 2021; 2021:7-14. PubMed
  • Hantel A, DuMontier C, Odejide OO, Luskin MR, Sperling AS, Hshieh T, Chen R, Soiffer R, Driver JA, Abel GA. Gait speed, survival, and recommended treatment intensity in older adults with blood cancer requiring treatment. Cancer 2020. PubMed
  • Luskin MR, DeAngelo DJ. Mini-Hyper-CVD Combinations for Older Adults: Results of Recent Trials and a Glimpse into the Future. Clin Lymphoma Myeloma Leuk 2020; 20 Suppl 1:S44-S47. PubMed
  • Luskin MR, Kim AS, Patel SS, Wright K, LeBoeuf NR, Lane AA. Evidence for separate transformation to acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm from a shared ancestral hematopoietic clone. Leuk Lymphoma 2020. PubMed
  • Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood 2019; 134:867-879. PubMed
  • Kayser S, Hills RK, Luskin MR, Brunner AM, Terré C, Westermann J, Menghrajani K, Shaw C, Baer MR, Elliott MA, Perl AE, Ráčil Z, Mayer J, Zak P, Szotkowski T, de Botton S, Grimwade D, Mayer K, Walter RB, Krämer A, Burnett AK, Ho AD, Platzbecker U, Thiede C, Ehninger G, Stone RM, Röllig C, Tallman MS, Estey EH, Müller-Tidow C, Russell NH, Schlenk RF, Levis MJ. Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia - results from an international collaborative study. Haematologica 2019. PubMed
  • Stern RM, Luskin MR, Clark RP, Miller AL, Loscalzo J. A Headache of a Diagnosis. N Engl J Med 2018; 379:475-479. PubMed
  • Luskin MR, Murakami MA, Manalis SR, Weinstock DM. Targeting minimal residual disease: a path to cure? Nat Rev Cancer 2018; 18:255-263. PubMed
  • Luskin MR, DeAngelo DJ. How to treat chronic myeloid leukemia (CML) in older adults. 2018. PubMed
  • Luskin MR. Chronic myeloid leukemia and pregnancy: patient and partner perspectives. Expert Rev Hematol 2018; 11:597-599. PubMed
  • Luskin MR, Abel GA. Management of older adults with myelodysplastic syndromes (MDS). 2017. PubMed
  • Luskin MR, DeAngelo DJ. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia. Expert Rev Hematol 2017; 10:1033-1045. PubMed
  • Luskin MR, Discenza MN, Easter SR, Dal Cin P, Owen R, Ilagan B, Masiello M, Lane AA. Maternal iAMP21 acute lymphoblastic leukemia detected on prenatal cell-free DNA genetic screening. Blood Adv 2017; 1:1491-1494. PubMed
  • Luskin MR, Stone RM. Can Minimal Residual Disease Determination in Acute Myeloid Leukemia Be Used in Clinical Practice? J Oncol Pract 2017; 13:471-480. PubMed
  • Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Battiwalla M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D'Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hashmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzieri D, Savani BN, Schouten HC, Sabloff M, Seftel M, Seo S, Sorror ML, Szer J, Wirk BM, Wood WA, Artz A. Increasing use of allogeneic hematopoietic cell transplantation in patients age 70 years and older in the United States. Blood 2017. PubMed
  • Luskin MR, DeAngelo DJ. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice. Curr Hematol Malig Rep 2017. PubMed
  • Luskin MR, Cronin AM, Owens RL, DeAngelo DJ, Stone RM, Wadleigh M, Steensma DP, Abel GA. Self-reported sleep disturbance and survival in myelodysplastic syndromes. British Journal of Haematology 2017. PubMed
  • Dinardo CD, Luskin MR, Carroll M, Smith C, Harrison J, Pierce S, Kornblau S, Konopleva M, Kadia T, Kantarjian H, Wertheim GB, Master SR. Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML. Am J Hematol 2017; 92:E14-E15. PubMed
  • Wertheim GBW, Luskin MR, Carroll M, Master SR. Microsphere-Based Assessment of DNA Methylation for AML Prognosis. Methods Mol Biol 2017; 1633:125-136. PubMed
  • Honigberg MC, Eshel N, Luskin MR, Shaykevich S, Lipsitz SR, Katz JT. Curricular Time, Patient Exposure, and Comfort Caring for Lesbian, Gay, Bisexual, and Transgender Patients Among Recent Medical Graduates. LGBT Health 2017; 4:237-239. PubMed
  • Banerjee R, Luskin MR, Loren AW. Late effects of blood and marrow transplantation. Haematologica 2017; 102:e465. PubMed
  • Luskin MR, Gimotty PA, Smith C, Loren AW, Figueroa ME, Harrison J, Sun Z, Tallman MS, Paietta EM, Litzow MR, Melnick AM, Levine RL, Fernandez HF, Luger SM, Carroll M, Master SR, Wertheim GB. A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia. JCI Insight 2016. PubMed
  • Luskin MR, Lee JW, Fernandez HF, Abdel-Wahab O, Bennett JM, Ketterling RP, Lazarus HM, Levine RL, Litzow MR, Paietta EM, Patel JP, Racevskis J, Rowe JM, Tallman MS, Sun Z, Luger SM. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood 2016; 127:1551-8. PubMed
  • Luskin MR, Ganetsky A, Landsburg DJ, Loren AW, Porter DL, Nasta SD, Svoboda J, Luger SM, Frey NV. Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma. British Journal of Haematology 2016; 174:332-4. PubMed
  • Sloan CE, Luskin MR, Boccuti AM, Sehgal AR, Zhao J, Daber RD, Morrissette JJ, Luger SM, Bagg A, Gimotty PA, Carroll M. A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia. PLoS ONE 2016; 11:e0153016. PubMed
  • Luskin MR, Carroll M, Lieberman D, Morrissette JJD, Zhao J, Crisalli L, Roth DB, Luger SM, Porter DL, Reshef R. Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 2016; 22:1961-1967. PubMed
  • Aikawa V, Porter D, Luskin MR, Bagg A, Morrissette JJ. Transmission of an expanding donor-derived del(20q) clone through allogeneic hematopoietic stem cell transplantation without the development of a hematologic neoplasm. Cancer Genet 2015; 208:625-9. PubMed
  • Luskin MR, Huen AO, Brooks SA, Stewart C, Watt CD, Morrissette JJ, Lieberman DB, Bagg A, Rosenbach M, Perl AE. NPM1 mutation is associated with leukemia cutis in acute myeloid leukemia with monocytic features. Haematologica 2015; 100:e412-4. PubMed
  • Luskin MR, Banerjee R, Del Percio S, Loren AW. A Pound of Cure Requires An Ounce (or More) of Prevention: Survivorship and Complications of Therapy for Hematologic Malignancies. Curr Hematol Malig Rep 2015; 10:225-36. PubMed
  • Reshef R, Huffman AP, Gao A, Luskin MR, Frey NV, Gill SI, Hexner EO, Kambayashi T, Loren AW, Luger SM, Mangan JK, Nasta SD, Richman LP, Sell M, Stadtmauer EA, Vonderheide RH, Mick R, Porter DL. High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. J Clin Oncol 2015; 33:2392-8. PubMed
  • Tsai DE, Luskin MR, Kremer BE, Chung AK, Arnoldi S, Paralkar VR, Nasta SD, Stadtmauer EA, Schuster SJ, Xavier M. A pilot trial of quantitative Epstein-Barr virus polymerase chain reaction in patients undergoing treatment for their malignancy: potential use of Epstein-Barr virus polymerase chain reaction in multiple cancer types. Leuk Lymphoma 2015; 56:1530-2. PubMed
  • Frosch Z, Luskin MR, Landsburg DJ, Schuster SJ, Svoboda J, Loren AW, Porter DL, Stadtmauer EA, Nasta SD. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 2015; 15:92-7. PubMed
  • Wertheim GB, Smith C, Luskin M, Rager A, Figueroa ME, Carroll M, Master SR. Validation of DNA methylation to predict outcome in acute myeloid leukemia by use of xMELP. Clin Chem 2015; 61:249-58. PubMed
  • Luskin M, Wertheim G, Morrissette J, Daber R, Biegel J, Wilmoth D, Kersun L, King R, Paessler M, Simon C, Aplenc R, Loren A. CLL/SLL diagnosed in an adolescent. Pediatr Blood Cancer 2014; 61:1107-10. PubMed
  • Luskin MR, Roy DB, Wasik MA, Loren AW. Development of lymphomas containing Epstein-Barr virus after therapy with hyper-CVAD regimen. Clin Lymphoma Myeloma Leuk 2014; 14:e55-8. PubMed
  • Laubach JP, Mitsiades CS, Mahindra A, Luskin MR, Rosenblatt J, Ghobrial IM, Schlossman RL, Avigan D, Raje N, Munshi NC, Anderson KC, Richardson PG. Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw 2011; 9:1209-16. PubMed
  • Tilton JC, Manion MM, Luskin MR, Johnson AJ, Patamawenu AA, Hallahan CW, Cogliano-Shutta NA, Mican JM, Davey RT, Kottilil S, Lifson JD, Metcalf JA, Lempicki RA, Connors M. Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished alpha interferon production in vitro. J Virol 2008; 82:3997-4006. PubMed
  • Tilton JC, Luskin MR, Johnson AJ, Manion M, Hallahan CW, Metcalf JA, McLaughlin M, Davey RT, Connors M. Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load. J Virol 2007; 81:2713-25. PubMed
  • Tilton JC, Johnson AJ, Luskin MR, Manion MM, Yang J, Adelsberger JW, Lempicki RA, Hallahan CW, McLaughlin M, Mican JM, Metcalf JA, Iyasere C, Connors M. Diminished production of monocyte proinflammatory cytokines during human immunodeficiency virus viremia is mediated by type I interferons. J Virol 2006; 80:11486-97. PubMed
  • Olshen E, Woods ER, Austin SB, Luskin M, Bauchner H. Parental acceptance of the human papillomavirus vaccine. J Adolesc Health 2005; 37:248-51. PubMed
Hide
Member Summary Video
Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Marlise R. Luskin, MD, MSCE but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members